<DOC>
	<DOCNO>NCT00004105</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase I/II trial study effectiveness vinorelbine , paclitaxel , estramustine treat patient advanced cancer respond previous treatment .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Advanced Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Establish maximum tolerated dos ( MTDs ) recommend Phase II dose ( RPTDs ) vinorelbine paclitaxel combine fix dose estramustine patient advance cancer metastatic prostate cancer . II . Determine toxicity pattern regimen MTDs RPTDs patient . III . Make preliminary observation antitumor activity patient treat regimen lead Phase II portion study . IV . Establish efficacy RPTDs vinorelbine paclitaxel combine estramustine patient prostate cancer fulfill criterion Phase II portion study . OUTLINE : This dose escalation , multicenter study vinorelbine paclitaxel . Patients receive oral estramustine every 8 hour day 0-2 7-9 vinorelbine IV 6-10 minute immediately follow paclitaxel IV 1 hour day 2 9 . Courses repeat every 21 day . Patients complete response , partial response , stable disease continue treatment indefinitely absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos vinorelbine paclitaxel maximum tolerate dose ( MTD ) drug determine . The MTD define low dose 2 3-6 patient experience dose limit toxicity . The recommended Phase II dose vinorelbine paclitaxel define dose immediately precede MTD . PROJECTED ACCRUAL : A minimum 12-16 patient accrue 1 year Phase I study total 14-25 patient accrue Phase II study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Estramustine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Phase I : Histologically proven advanced cancer fail amenable standard treatment Phase II : Histologically proven metastatic prostate cancer document bone scan rise PSA Measurable evaluable disease PATIENT CHARACTERISTICS : Age : 18 Performance status : 02 Life expectancy : Not specify Hematopoietic : Neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin great 9 g/dL ( transfusion allow ) Hepatic : AST ALT great 4 time upper limit normal Bilirubin great 2 mg/dL Renal : Creatinine great 2 mg/dL Cardiovascular : No myocardial infarction within past year No New York Heart Association class III IV heart disease No uncontrolled cardiac dysrhythmia No angina pectoris No uncontrolled hypertension No cardiomyopathy Neurologic : No prior neuropathy No preexisting neurotoxicity Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Phase I : No prior vinorelbine ( schedule ) paclitaxel 24 hour long schedule At least 2 week since prior chemotherapy Phase II : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No radiotherapy great 25 % bone marrow At least 3 week since prior radiotherapy No concurrent radiotherapy course 1 2 . Surgery : No concurrent oncologic surgery course 1 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>childhood fibrosarcoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>